Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil

Israel Medical Association Journal

Volumn 7, Issue 8, 2005, Pages 520-524

  Niv, Yaron ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Chemotherapy; Colorectal cancer treatment; Microsatellite instability

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

AGING; ALOPECIA; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DRUG CYTOTOXICITY; DRUG MECHANISM; GENETIC STABILITY; HUMAN; IN VITRO STUDY; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; NAUSEA; NEUROLOGIC DISEASE; PATIENT SELECTION; PHENOTYPE; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; MICROSATELLITE REPEATS; SURVIVAL RATE;

EID: 23344437954     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-6
3. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-61.
4. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-19.
5. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-16.
6. Carethers JM, Boland CR. Neoplasia of the gastrointestinal tract. In: Yamada T, Alpers DH, Kaplowitz N, Laine L, Owyang C, Powell DW, eds. Gastrointestinal Diseases. Philadelphia: Lippincott-Raven, 2003:557-83.
7. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-5.
8. Viegl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998; 95:8698-702.
9. Lothe RA, Peltomaki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993 53:5849-52.
10. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
11. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-303.
12. Lukish JR, Muro K, DeNobile J, et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 1998;227:51-6.
13. Bubb VJ, Curtis LJ, Cunningham C, et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996;12:2641-9.
14. Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000;87:1197-202.
15. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 Gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Duke's C colon carcinoma. Oncology 2000;58:52-9.
16. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in cotorectal cancer. Lancet 2000;355:1745-50.
17. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117: 123-31.
18. Merkelbach-Bruse S, Hans V, Mathiak M, et al. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. Oncol Rep 2004, 11:839-43.
19. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003;106:66-73.
20. Claij N, te Riele H. Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res 1999;246:1-10.
21. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
22. Anthoney DA, McIlwrath AK, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996;56:1374-81.
23. Kat A, Thilly WG, Fang W-H, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993;90:6424-8.
24. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993;362:652-4.
25. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001;61:5193-201.
26. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-8.
27. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126:394-401.
28. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004;109:468-71.
29. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
30. Brueckl WM, Moesch C, Brabletz T, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 2003;23:1773-7.
31. Liang J-T, Huang K-C, Lai H-S, et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002;101:519-25.
32. Boland CR, Thibodeau SN, Hamilton SR, et al. The International Workshop on Microsatellite Instability and RER phenotypes in cancer detection and familial predisposition. Cancer Res 1998;58:5248-57.
33. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
34. Goel A, Arnold CN, Tassone P, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004;112:754-9.
35. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001;1:104-9.
36. Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002;360:1381-91.
37. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990;48:381-95.
38. Ingraham HA, Tseng BY, Goulian M. Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res 1980;40:998-1001.
39. Lonn U, Lonn S. DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines. Cancer Res 1986;46:3866-70.